New York, NY, United States of America

Mithat Gonen

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: Cornell University, Memorial Sloan Kettering Cancer Center. Active years: 2026.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Mithat Gonen

Introduction

Mithat Gonen is a prominent inventor based in New York, NY (US). He has made significant contributions to the field of cancer research through his innovative patent. His work focuses on enhancing the understanding and treatment of cancer using advanced imaging systems.

Latest Patents

Mithat Gonen holds a patent titled "Imaging systems and methods for particle-driven, knowledge-based, and predictive cancer radiogenomics." This patent describes systems and methods that utilize particle-driven radiogenomics to identify imaging features for predicting nanoparticle distributions in various cancers, including gliomas. The techniques outlined in this patent improve the quantitative ability to measure treatment responses and determine tumor progression compared to traditional imaging methods.

Career Highlights

Throughout his career, Mithat Gonen has worked with esteemed institutions such as Memorial Sloan Kettering Cancer Center and Cornell University. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Mithat Gonen has collaborated with notable colleagues, including Michelle S. Bradbury and Cameron Brennan. These partnerships have further enriched his research and innovation in cancer radiogenomics.

Conclusion

Mithat Gonen's contributions to cancer research through his innovative patent and collaborations with leading institutions highlight his commitment to advancing medical science. His work continues to pave the way for improved cancer treatment methodologies.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…